



Journal of Cellular Biochemistry 105:370–380 (2008)Annexin II/Annexin II Receptor Axis Regulates Adhesion,








Yusuke Shiozawa,1 Aaron M. Havens,1,2 Younghun Jung,1 Anne M. Ziegler,1
Elisabeth A. Pedersen,1 Jingcheng Wang,1 Jianhua Wang,1 Ganwei Lu,3
G. David Roodman,3 Robert D. Loberg,4 Kenneth J. Pienta,4 and Russell S. Taichman1*
1Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, Michigan
2Harvard School of Dental Medicine, Boston, Massachusetts
3Medicine-Hematology/Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania
4Department of Internal Medicine, Division of Hemotology/Oncology, University of Michigan School of Medicine,
Ann Arbor, MichiganABSTRACT
One of the most life-threatening complications of prostate cancer is skeletal metastasis. In order to develop treatment for metastasis, it is
important to understand its molecular mechanisms. Our work in this field has drawn parallels between hematopoietic stem cell and prostate
cancer homing to the marrow. Our recent work demonstrated that annexin II expressed by osteoblasts and endothelial cells plays a critical role
in niche selection. In this study, we demonstrate that annexin II and its receptor play a crucial role in establishing metastasis of prostate cancer.
Prostate cancer cell lines migrate toward annexin II and the adhesion of prostate cancer to osteoblasts and endothelial cells was inhibited by
annexin II. By blocking annexin II or its receptor in animal models, short-term and long-term localization of prostate cancers are limited.
Annexin II may also facilitate the growth of prostate cancer in vitro and in vivo by the MAPK pathway. These data strongly suggest that
annexin II and its receptor axis plays a central role in prostate cancer metastasis, and that prostate cancer utilize the hematopoietic stem cell
homing mechanisms to gain access to the niche. J. Cell. Biochem. 105: 370–380, 2008.  2008 Wiley-Liss, Inc.KEY WORDS: ANNEXIN II; ANNEXIN II RECEPTOR; PROSTATE CANCER; METASTASIS; NICHEC ancer of the prostate gland (PCa), as well as those arisingin many other tissues, displays a remarkable propensity to
invade and survive in bone. Nearly 10% of patients present with
bone metastasis, and almost all patients who die of PCa have skeletal
involvement [Coleman, 2006]. Therefore, identifying the molecular
mechanisms that regulate osseous metastasis is of clinical
importance so as to determine those individuals at greatest risk
for the development of metastasis. This research may also help
design therapeutics aimed at decreasing metastatic risk or their
complications.
The metastatic process is functionally similar to the migrational
or ‘‘homing’’ behavior of hematopoietic stem cells (HSC) to the bone
marrow. Numerous molecules have been implicated in regulating
HSC homing, participating as both chemoattractants and regulators
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a result, we identified that PCa cells use the CXC chemokine CXCL12
or SDF-1 and its receptors CXCR4 [Taichman et al., 2002; Sun et al.,
2003, 2005; Wang et al., 2005] and CXCR7/RDC1 [Wang et al., 2008]
as key elements in metastasis and growth in bone.
Identification of the HSC niche in the marrow is an active area of
investigation [Calvi et al., 2003; Zhang et al., 2003; Arai et al., 2004;
Kiel et al., 2005; Taichman, 2005]. One protein in high abundance in
the marrow is annexin II (Anxa2) (or p36, calpactin I heavy chain,
and lipocortin II [Raynal and Pollard, 1994]). Anxa2 is a 36 kDa
peripheral membrane protein expressed by endothelial cells, early
myeloid cells, some tumor cells [Menell et al., 1999; Brownstein
et al., 2001; Falcone et al., 2001], and osteoblasts [Takahashi et al.,
1994; Wang and Kirsch, 2002; Jung et al., 2007]. Anxa2 exists as a
monomer, a heterodimer, or a heterotetramer [Gerke and Weber,370
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1984; Glenney, 1986]. Anxa2 tetramer is composed of two copies of
a 36 kDa heavy chain (Anxa2 or p36), and two 11 kDa light chains
(p11) [Gerke and Weber, 1984]. The protein itself has two structural
domains; an amino-terminal domain, which includes the first
30 amino acids of the p36 heavy chain, the serine and tyrosine
phosphorylation sites and sites for binding the p11 light chain
[Glenney, 1986]. The formation of the heterotetramer permits
binding to the plasma membrane [Thiel et al., 1992]. The expression
of Anxa2 is known to be regulated by insulin, fibroblast growth
factor (FGF), and epidermal growth factor (EGF) [Zhao et al., 2003].
Enhanced Anxa2 expression has also been reported in human
hepatocellular carcinoma, pancreatic adenocarcinoma, high-grade
glioma, gastric carcinoma, and acute promyelocytic leukemia [Diaz
et al., 2004]. Anxa2 is known to interact with a number of
extracellular matrix molecules such as tenascin-C and proteolytic
enzymes including tissue plasminogen activator (t-PA) and
cathepsin B [Chung and Erickson, 1994; Fitzpatrick et al., 2000;
Mai et al., 2000]. Accordingly, Anxa2 may participate in
plasminogen activation, cell adhesion, and tumor metastasis and
invasion.
Based upon its distribution in marrow, Anxa2 is likely to play
several roles in regulating hematopoiesis. On endothelium, Anxa2
regulates the plasmin/plasminogen activator system and may play a
role in fibrinolytic surveillance by anchoring key components of the
fibrinolytic cascade [Brownstein et al., 2001; Falcone et al., 2001].
Anxa2 is known to serve as a binding site for beta 2-glycoprotein I,
a phospholipid-binding protein from plasma [Baran et al., 2000].
Other ligands include a vitamin D analog that is inhibited in rat
osteoblasts by Ca2þ [Baran et al., 2000]. In bone, Anxa2 has been
demonstrated to play a role in osteoclastic activation and osteoblast
mineralization, although the mechanisms for these actions remain
unclear [Takahashi et al., 1994; Wang and Kirsch, 2002]. One
scenario is that extracellular Anxa2 levels are regulated by 1,25-
dihydroxyvitamin D3 that stimulates the proliferation of osteo-
clastic precursors possibly through T-cell intermediaries to secrete
granulocyte-macrophage colony stimulating factor (GM-CSF)
[Menaa et al., 1999].
Our recent work in this field has demonstrated that Anxa2
expressed by osteoblasts and endothelial cells plays a critical role in
niche selection [Jung et al., 2007]. We have demonstrated that the
engraftment of HSCs and survival of lethally irradiated animals
during experimental bone marrow transplantation are sharply
curtailed in the presence of neutralizing Anxa2 antibodies, and N-
terminal Anxa2 peptides [Jung et al., 2007]. Moreover, fewer HSCs
are found in the marrows of Anxa2-deficient animals. Among the
most compelling mechanisms to account for these observations is
that Anxa2 acts as an adhesion ligand for HSCs homing [Jung et al.,
2007].
In this study, we draw parallels between PCa metastasis and
HSC homing to the niche. Anxa2 itself is associated with
proliferating and invasive cancers, possibly as a marker of
malignancy [Reeves et al., 1992] including lung, pancreatic, brain,
colon, and gastric carcinomas, and is correlated with poor prognosis
[Cole et al., 1992; Vishwanatha et al., 1993; Roseman et al., 1994;
Emoto et al., 2001; Diaz et al., 2004]. Yet, the loss of Anxa2
expression appears to be specific for PCa disease [Chetcuti et al.,JOURNAL OF CELLULAR BIOCHEMISTRY2001; Banerjee et al., 2003; Kirshner et al., 2003; Liu et al., 2003;
Smitherman et al., 2004; Semov et al., 2005]. Our finding indicates
that Anxa2 serves as an adhesion molecule for PCa, and blocking
Anxa2 or its receptor limits metastasis in animal models. Anxa2 may
also facilitate the growth of PCa in vitro and in vivo via partially
through activation of the MAPK pathway. Taken together, these data
strongly suggest that annexin II plays a central role in PCa
metastasis, and that PCa utilize HSC homing mechanisms to gain
access to the niche.MATERIALS AND METHODS
CELL CULTURE
PC-3 (CRL-1435), DU145 (HTB-81), and LNCaP (CRL-1740) prostate
cancer cell lines were obtained from the American Type Culture
Collection (Rockville, MD). The metastatic subline LNCaP C4-2B
were originally isolated from a lymph node of a patient with
disseminated bony and lymph node involvement [Wu et al., 1998].
PC-3Luc cells were constructed by stably transfecting PC-3 cells with
luciferase construct, as previously described [Loberg et al., 2006].
The human bone marrow endothelial cells (HBMECs) were isolated
from a normal Caucasian male and immortalized with SV40 large
T-antigen [Lehr and Pienta, 1998]. Cells were cultured in RPMI 1640
(Invitrogen, Carlsbad, CA) and were supplemented with 10% fetal
bovine serum (FBS; Invitrogen) and 1% penicillin-streptomycin
(Invitrogen), and maintained at 378C, 5% CO2, and 100% humidity.
Anxa2 RECEPTOR (Anxa2r) SILENCING
A 60-bp oligonucleotide, containing 19-nucleotides to a portion of
the human Anxa2r and its reverse complement sequences separated
by a 9-nucleotide spacer sequence, were subcloned into the
BglII and HindIII restriction sites of the 3.2-kb plasmid pSUPER
containing the H1-RNA promoter (Oligoengine, Seattle, WA). PC-
3Luc cells were transfected with siRNA Anxa2r vectors (PC-3siAnxa2r
cells) and a scrambled control (PC-3siControl cells) using Superfect
(QIAGEN, Valencia, CA) as described previously [Jung et al., 2007].
siRNA knock down was monitored by real-time reverse transcrip-
tion-polymerase chain reaction (QPCR).
HUMAN OSTEOBLASTS
Human osteoblasts were established by explant culture from
normal human trabecular bone obtained from patients undergoing
orthopedic surgery in accordance with the University of Michigan’s
Investigational Review Board, as previously described [Taichman
and Emerson, 1994].
ISOLATION OF PRIMARY MURINE CALVARIAL CELLS
Primary calvarial cells were isolated, as previously described
[Koh et al., 2005]. Briefly, calvariae of mice (1- to 4-day-old) were
dissected, isolated from periosteum, and subjected to sequential
digestions of 20, 40, and 90 min in collagenase A (2 mg/ml; Roche
Molecular Biochemicals, Indianapolis, IN) with 0.25% trypsin
(Invitrogen). Cells from the third digestion were plated in a-MEM
(Invitrogen) with 10% FBS and 1% penicillin and streptomycin.ANNEXIN I I REGULATES METASTASIS 371
MURINE MODELS
All experimental procedures were approved by the University of
Michigan Committee for the Use and Care of Animals (UCUCA).
C57BL6 mice, male severe combined immune deficient (SCID) mice
(5–6 weeks of age), and male athymic (nude) mice (4–6 weeks of age)
were purchased from Harlan Bioscience (Indianapolis, IN). The
laboratory of Dr K.A. Hajjar (Weill Medical College of Cornell
University, New York, NY) generated the Anxa2-deficient (Anxa2/)
animals used in our study and graciously provided our laboratory
with a pair of the homozygous Anxa2/ mice for breeding.
ANTIBODIES AND REAGENTS
The anti-Anxa2 antibody (Clone 5; mouse IgG1) was purchased from
BD Pharmingen (San Diego, CA). Antibodies targeting Anxa2r were
generated in the laboratory of Dr. G.D. Roodman (University of
Pittsburgh, Pittsburgh, PA) and were described in detail previously
[Lu et al., 2006]. The antibodies to phosphorylated Akt (Ser473),
total Akt, phosphorylated p44/42 MAP kinase (Thr202/Tyr204),
total p44/42 MAP kinase, and horseradish peroxidase (HRP)-labeled
goat anti-rabbit IgG (Hþ L) were obtained from Cell Signaling
Technology (Danvers, MA). The control antibodies for these
investigations included immonoglobulin Ig G1k (clone MOPC
31C; Sigma–Aldrich, St. Louis, MO), IgG1 (clone X40; Becton-
Dickinson, San Jose, CA), IgG2a (clone 20102; R&D Systems,
Minneapolis, MN). Purified bovine lung Anxa2 was purchased from
Biodesign International (Saco, ME). Anxa2 N-terminal peptide
corresponding to the 1–12 amino acids and a random peptide
(TVLLHEICKSSL) were synthesized, as previously detailed [Jung
et al., 2007]. Recombinant human CXCL12 was purchased from R&D
Systems.
IMMUNOHISTOCHEMISTRY
Murine bones were harvested and fixed in 10% buffered formalin
and decalcified in EDTA, and 2–3 mM paraffin-embedded slides
were prepared and stained with antibody to Anxa2 or an IgG
matched isotype control in conjunction with a HRP-AEC staining
system kit using anti-mouse biotinylated antibodies following the
manufactures protocols (R&D Systems).
Human osteoblasts were cultured in Lab-Tek II 4-chamber slides
(Nalge Nunc International, Naperville, IL) at 5 104 cells/chamber.
After 24 h, fixed in 4% paraformaldehyde for 25 min at room
temperature, washed and endogenous peroxidase activity quenched
with 75 mM NH4Cl and 20 mM Glycine in PBS at room temperature
for 10 min. Thereafter, primary antibody incubations at a 1:200
dilution in PBS using the anti-Anxa2 or an IgG matched isotype
control for 1 h at room temperature. Antibody detection was
performed using an HRP-AEC staining kit (R&D Systems), and
counter stained with hematoxylin (Sigma–Aldrich).
BINDING ASSAYS
Anxa2 binding assays were performed with purified bovine lung
Anxa2 or Bovine Serum Albumin (BSA; Sigma–Aldrich) plated into
96-well plates for 24 h at 48C, washed, and then blocked with 0.1%
BSA for 2 h.
For cell-to-cell binding assays, the human osteoblasts, murine
calvarial cells, and HBMECs were plated onto 96-well plates at a372 ANNEXIN II REGULATES METASTASISconcentration of 10,000 cells per well (100 ml per well) in growth
mediums, and the cultures were incubated for 2 days.
PC-3, PC-3siAnxa2r, or PC-3siControl cells were labeled with 2.5 mg/
ml of the lipophilic dye carboxyfluorescein diacetate (CFDA;
Molecular Probes, Eugene, OR) in RPMI for 30 min at 378C, and
washed in PBS. Thereafter, the cells were left for 30 min to reduce
nonspecific background, and subsequently resuspended in PBS to
deliver 105 cells/well in the adhesion assay. Adhesion assays were
performed in PBS containing Caþ2/Mgþ2 where the cells were added
to a final reaction volume of 100 ml at 48C. After washing
fluorescence was quantified. In some cases, the cells were incubated
in 5 mg/ml of an anti-Anxa2 or IgG matched isotype control
antibody, or 1 mg/ml of an Anxa2 N-terminal peptide or a random
peptide control to block adhesion for 15 min on ice prior to seeding
onto the monolayers.
TRANSWELL CHEMOTAXIS ASSAYS
Cell invasion into a reconstituted extracellular matrices coating of
MatrigelTM overlaid on 8 mM pore sized in polyethylene terephtha-
late membranes was performed in dual chambered invasion plates
(BD Biosciences, San Jose, CA) as previously described [Sun et al.,
2007; Wang et al., 2008]. Spontaneous invasion was compared to
invasion supported by Anxa2. For blocking studies, rhCXCL12 at a
final concentration of 200 ng/ml was added to the lower chamber,
and Anxa2 N-terminal peptide or a random peptide control at a final
concentration of 1 mg/ml was added to the upper chamber along
with the cells.
REVERSE TRANSCRIPTION-PCR (RT-PCR) AND QPCR
RT-PCR and QPCR was carried out using standard techniques.
Briefly, total RNA was isolated using RNeasy Mini Kit (QIAGEN), and
first-strand cDNA was synthesized in a 20 ml reaction volume using
0.4 mg of total RNA. The sequences of the forward and reverse
primers of Anxa2r were 50-CGGAGTCTACTGGCAAAACG-30 and 50-
GCCTTCTGCTGCTATCTAAG-30. The reaction profile was 948C for
1 min, 608C for 1 min, and 728C for 2 min for 35 cycles, followed
by a 10-min extension at 728C. PCR products were separated by
electrophoresis in 1.2% agarose gels and visualized by ethidium
bromide staining.
RT products were analyzed by QPCR in TaqMan1 Gene Expres-
sion Assays of several target genes: Anxa2r (Hs01588662_s1) and
b-actin (Hs99999903_m1) (Applied Biosystems, Foster City, CA).
QPCR analysis was performed using 15.0 ml of TaqMan1 Universal
PCR Master Mix (Applied Biosystems), 1.5 ml of TaqMan1 Gene
Expression Assay (forward and reverse primers at 18 mM and
Taqman probe at 5 mM), 1 ml of the RT product, and 12.5 ml
of RNAse/DNAse-free water in a total volume of 30 ml. Reactions
without template and/or enzyme were used as negative controls. The
2nd step PCR reaction (958C for 30 s, 608C) was run for 40 cycles
after an initial single cycle of 958C for 15 min to activate the Taq
polymerase. The PCR product was detected as an increase in fluore-
scence using an ABI PRISM 7700 instrument (Applied Biosystems).
RNA quantity (CR) was normalized to the housekeeping gene b-Actin
control by using the formula CR¼ 2(40-Ct of sample)-(40-Ct of control). The
threshold cycle (Ct) is the cycle at which a significant increase in
fluorescence occurs.JOURNAL OF CELLULAR BIOCHEMISTRY
TISSUE MICROARRAY AND IMMUNOSTAINING
Human prostate adenocarcinoma tissue microarray was purchased
from US Biomax, Inc. (Rockville, MD). Tumors were graded using the
Gleason grading system and examined to identify areas of benign
prostate, prostate cancer and bone metastasis. The formalin-fixed,
paraffin-embedded tissues were deparaffinized and placed in a
pressure cooker containing 0.01 M buffered sodium citrate solution
(pH 6.0), boiled and chilled to room temp for antigen retrieval. The
slides were incubated overnight at room temperature with anti-
Anxa2r antibody diluted 1:100. A blinded pathologist analyzed
arrays and staining intensity was ranked on a scale from 0 to 3 (0,
negative; 1, weak; 2, moderate; and 3, strong intensity staining).
Anxa2 TREATMENTS
PC-3 cells (1 106) were cultured in six-well plates in RPMI medium
(1 ml) without FBS for 5 h. After serum starvation, the cells were
treated with 1,000 ng/ml Anxa2 for 5, 15, 30, 45, and 60 min. The
cells were extracted for protein and analyzed for phosphorylated
p44/42 MAP kinase (Thr202/Tyr204) and for phosphorylated Akt by
Western blotting analysis. Total p44/42 MAP kinase and Akt were
used as an internal control for loading.
PROLIFERATION ASSAYS
The murine calvarial cells from Anxa2þ/þ or Anxa2/ mice were
plated into triplicate 96-well plates at a concentration of 10,000 cells
per well (100 ml per well) in growth medium with 0.1% FBS. The
next day, PC-3Luc cells were added to the wells at a concentration of
5,000 cells per well. Thereafter, the cultures were incubated in an
atmosphere of 5% CO2 and 95% O2 at 378C for 3 days. Proliferation
was determined by using a CCD IVIS system with a 50-mm lens
(Xenogen Corp., Alameda, CA) and the results were analyzed using
LivingImage software (Xenogen Corp.).
IN VIVO METASTASIS ASSAYS
PC-3Luc cells were introduced into male SCID mice by intracardiac
(i.c.) injections. Immediately prior, the recipient mice were
inoculated by intraperitoneal (i.p.) injections with (i) anti-Anxa2
antibody, (ii) the Anxa2 N-terminal peptide, or (iii) a mixed IgG
matched isotype control antibodies/random peptide control each at
10 mg/kg. Short-term engraftment was assessed at 12 h by QPCR
using for luciferase 2CP gene [luc2CP, CGGCTGGCAGAAGCTAT-
GAA (forward), TCGCTGCACACCACGAT (reverse), and 50-FAM-
CTATGGGCTGAATACAAACC (TaqMan probe; Applied Biosystems)].
Data were normalized to mouse tissue b-actin (mm00607939-s1).
PC-3siAnxa2r or PC-3siControl cells were used to assess the role of
Anxa2 in long-term PCa homing.
BIOLUMINESCENT IMAGING (BLI)
BLI was done as previously described through The University of
Michigan Small Animal Imaging Resource facility [Loberg et al.,
2007]. Briefly, cells were introduced into male SCID mice by i.c.
injections. Mice were imaged at 30 days by BLI. Mice were injected
with luciferin (40 mg/ml) by i.p. injections and ventral images
were acquired 15 min postinjection under 1.75% isofluorane/air
anesthesia. Total tumor burden of each animal was calculated using
regions of interest (ROI) that encompassed the entire animal.JOURNAL OF CELLULAR BIOCHEMISTRYVERTEBRAL BODY TRANSPLANTS (VOSSICLES)
Lumbar vertebrae were isolated from Anxa2þ/þ or Anxa2/ mice
7 days after birth. The vertebrae were sectioned into single vertebral
bodies (vossicles). Athymic (nude) mice were used as transplant
recipients. Four vossicles per mouse were implanted into sub-
cutaneous (s.c.) pouches. Before implantations, PC-3Luc cells were
introduced into both vossicles (10,000 cells/10 ml of PBS). Mice were
imaged at 30 days by BLI.
STATISTICAL ANALYSES
All in vitro experiments were performed at least three times with
similar results and representative assay are shown. Numerical data
are expressed as mean standard error. Statistical analysis was
performed by ANOVA or Student’s t-test using the GraphPad Instat
statistical program (GraphPad Software, San Diego, CA) with
significance at P< 0.05. For the QPCR assays, a Kruskal–Wallis test
and Dunn’s multiple comparisons tests were utilized with the level of
significance set at P< 0.05.
RESULTS
Anxa2 IS EXPRESSED ON OSTEOBLASTS SURFACE IN BONE
MARROW
To determine whether Anxa2 is expressed at the sites relevant to the
localization of PCa to the bone marrow endosteal and endothelial
niches, immunohistochemistry for Anxa2 was performed. As
demonstrated in Figure 1A, Anxa2 immunoreactivity was most
intense at the endosteal osteoblastic surfaces of the marrow closest
the growth plate (Fig. 1A-1,2). In some cases, bone marrow
endothelial cells also displayed immunoreactivity towards Anxa2
(Fig. 1A-1,3). No signal was observed in the absence of the specific
anti-Anxa2 antibody (Fig. 1A-4) and the bone marrow from
Anxa2/ mice (Fig. 1A-5). Human primary osteoblasts also
demonstrated perinuclear and cytoplasmic expression of Anxa2
in nearly all of the cells under basal conditions (Fig. 1B). These
findings suggest that Anxa2 is expressed on osteoblasts in the bone
marrow.
PCa BINDS AND MIGRATES TOWARDS Anxa2
Our recent studies demonstrate that HSCs use Anxa2 to bind to
endothelial cells and osteoblasts [Jung et al., 2007]. Studies were
therefore undertaken to determine if Anxa2 serves as an adhesive
molecule for PCa. PC-3 cells bind to Anxa2 in a dose dependent
manner (Fig. 2A-1), and other PCa cell lines not shown). Cell-to-cell
adhesion assays were next performed using a bone marrow
endothelial cells and osteoblasts that express abundant Anxa2.
Here, the PCa cells bound rapidly to the HBMEC cells and the Anxa2
N-terminal competing peptide significantly reduced PC-3 cells
binding to HBMECs compared to a scrambled control peptide
(Fig. 2A-2). Next, we performed the binding assays between PC-3
cells and human or murine osteoblasts. The data demonstrate that
the binding of PC-3 cells to human osteoblasts was significantly
inhibited using antibody to Anxa2 (Fig. 2B-1). When the binding of
PC-3 cells to osteoblasts derived from Anxa2þ/þ or Anxa2/ mice
was evaluated, it was noted that significantly more PC-3 cells boundANNEXIN I I REGULATES METASTASIS 373
Fig. 1. Anxa2 protein is expressed in bone. A: Expression of Anxa2 protein in
murine long bones. Mouse tibias were fixed in 10% formalin at 48C before
being decalcified in 10% EDTA (pH 7.4) and embedded in paraffin wax.
Immunolocalization of Anxa2 protein was visualized using a monoclonal
antibody (mAb) to Anxa2 or an IgG isotype matched control antibody. A-1:
Anxa2-immunostained tibias (20 magnification). A-2: Higher magnification
of (A-1) at 40 magnification and Anxa2 expression at the epiphyseal growth
plates. A-3: Higher magnification of (A-1) at 40 magnification and Anxa2
expression at the bone marrow endothelial cells. A-4: IgG control (20
magnification). A-5: No Anxa2 expression in the tibia of Anxa2/ animals
(20 magnification). B: Expression of Anxa2 protein by primary human
osteoblasts stained with anti-Anxa2 mAb or an IgG isotype matched control
(20 magnification). B-1: IgG control immunoactivity on the human osteo-
blasts. B-2: Anxa2 expression on the human osteoblasts. Scale bars¼ 100 mm.to the Anxa2þ/þ osteoblasts than to the Anxa2/ osteoblasts
(Fig. 2B-2).
Once tumor cells have adhered to and moved through the
endothelium, they must invade through the extracellular matrix.
The ability of Anxa2 to influence PCa invasion was studied using a
reconstituted extracellular matrix in porous chambers. PC-3 cells
were placed in the upper chamber in serum free medium, whereas
Anxa2 at increasing doses was placed in the lower chamber to
establish a chemoattractive gradient. After 8 h, quantification of the
cells migrating into the reconstituted matrix in triplicate assays was
performed. Anxa2 supported the invasion of PC-3 cells into the
reconstituted matrix (Fig. 2C). To further determine if Anxa2 is used
to localize PCa cells to tissue spaces, CXCL12 was employed to
establish a chemoattractive gradient [Taichman et al., 2002]. When
rhCXCL12 was placed in the bottom chamber, PC-3 cells migrated
towards the chemokine (Fig. 2D). When Anxa2 was added to the374 ANNEXIN II REGULATES METASTASISupper chamber of the culture dish with rhCXCL12 present in the
bottom, fewer PC-3 cells migrated towards the chemokine CXCL12.
Similar results were observed when an N-terminal competing Anxa2
peptide was included in the assay (Fig. 2D). These data support the
notion that PCa binds to, and moves toward Anxa2, and further
suggests that Anxa2 participates in tissue localization of PCa.
Anxa2 IS INVOLVED IN PCa METASTASIS
In order to test our hypothesis that Anxa2 is critical for the
development of metastases in vivo, we established three experi-
mental groups. In each case, the animals were inoculated with
PC-3Luc cells by i.c. injection. Immediately prior to the i.c. injection,
the animals were injected i.p. with (i) an antibody to Anxa2, (ii) the
N-terminal competing Anxa2 peptide, or (iii) an isotype matched,
nonspecific antibody combined with a scrambled the amino acid
sequence of the N-terminal competing peptide. The animals were
subsequently sacrificed at 12 h and tissues were harvested. QPCR
was utilized as our primary outcome to detect the tagged human
cells. As shown in Figure 3, all of the animals in injected with PC-3
cells alone demonstrated significant homing/lodging of the cancer
cells in a number of tissues. Animals injected with antibody to
Anxa2 and the Anxa2 N-terminal competing peptide significantly
reduced the total metastatic load of the animals compared to the
IgG/peptide treated control group. Animals not injected with human
cells did not demonstrate any signal for luciferase (data not shown).
These data suggested that Anxa2 plays an important role in short-
term homing of PCa and regulates PCa metastasis.
Anxa2r EXPRESSED ON PCa
A single pass Anxa2r membrane receptor was cloned and identified
to bind the p11 fraction of Anxa2 (Anxa2r) [Lu et al., 2006]. To
determine if PCa cells express the Anxa2r, RT-PCR and QPCR for the
Anxa2r was performed. As demonstrated in Figure 4A, PC-3 cells
expressed mRNA for the Anxa2r. We also performed QPCR for 4
different human PCa cell lines to compare their expression levels.
The Anxa2r mRNA was most strongly expressed by the DU145 cell
line (Fig. 4B). Modest expression was seen in the PC-3, LNCaP, and
C4-2B cell lines (Fig. 4B). Next, to evaluate the widest range of
Anxa2r expression, PCa tissue microarrays were examined. Tumors
were graded using the Gleason grading system and examined to
identify areas of benign prostate and PCa. Staining of microarrays
with antibody to Anxa2r revealed moderate-to-strong Anxa2r
protein expression in clinically localized PCa samples with
cytoplasmic and nuclear localization (Fig. 4C-1–6). Anxa2r protein
expression was enhanced with increasing tumor grade, although
statistically there were no significant differences in localized tumor
and metastatic lesions (Fig. 4C-1–6, and data not presented).
Anxa2r INVOLVED IN PCa METASTASIS
To test whether Anxa2r is also critical for the development of
metastases, siRNAs were employed to alter the expression of Anxa2r
on PCa cells. PC-3Luc cells were transfected with siRNAs targeting
the Anxa2r. Our best siRNA was able to decrease Anxa2r mRNA
expression by  60% by 48h (Fig. 5A). By knocking down the
Anxa2r, PCa cells bind less vigorously to HBMECs compared withJOURNAL OF CELLULAR BIOCHEMISTRY
Fig. 2. Anxa2 regulates the adhesion of prostate cancer and prostate cancer invasion. A-1: Fluorescently labeled PC-3 cells were deposited directly into wells containing
different concentrations (0–1,000 ng/ml) of purified bovine lung Anxa2 peptide and adhesion determined. A-2: PC-3 cells were layered on human bone marrow endothelial cells
(HBMECs) in the presence of N-terminal Anxa2 peptide or a scramble control peptide. B-1: PC-3 cells were layered on human osteoblasts in the absence or presence of an anti-
Anxa2 antibody or an isotype matched IgG control antibody (5 mg/ml). B-2: PC-3 cells were layered on wild-type murine osteoblasts (Anxa2þ/þ OBs) or Anxa2/ murine
osteoblasts (Anxa2/ OBs). After 15 min incubation at 48C, the non-adherent cells were removed. The number of adherent cells was quantified using a fluorescence plate reader.
Data are presented as the mean standard error percentage of adherent cells from three independent experiments. 	P< 0.05 and #P< 0.01 versus control by ANOVA. Invasion of
PC3 cells into matrigel was used to evaluate the effects of Anxa2 on invasion. C: Matrigel invasion assays were performed with different concentrations of purified bovine lung
Anxa2 peptide on PC-3 cell invasion. In (D), Matrigel invasion assays were used to evaluate the effect of neutralizing Anxa2 on the invasion of PC-3 cells in response to a
chemotactic gradient established by CXCL12. Purified bovine lung Anxa2 or N-terminal Anxa2 or control peptides were seeded on the upper well of a Transwell chamber. The
rhCXCL12 was added in the lower well (200 ng/ml). The results of at least three independent replicates are shown. #P< 0.01 versus control by ANOVA.
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Fig. 3. Anxa2 regulates short term homing of prostate cancer in vivo to bone.
PC-3Luc cells were administered by intracadiac injection into SCID mice in
the presence of antibody to Anxa2, an N-terminal Anxa2 peptide, or mixed
IgG matched isotype control antibodies and random peptide controls each at
10 mg/kg. The short-term homing capabilities of the prostate cancer were
evaluated at 12 h. The level of engraftment was assessed by QPCR for luciferase
and data were normalized to total mouse b-actin. Data are presented as the
mean standard error (n¼ 5) where significance was determined using a
Kruskal-Wallis test and Dunn’s multiple comparisons with the level of sig-
nificance set at 	P< 0.05.
Fig. 4. Prostate cancer expresses Anxa2r. A: Representative conventional
RT-PCR analysis of Anxa2r expression in PC-3 cell line. KG1a cells (acute
myeloid leukemia cell line) served as positive controls for Anxa2r and
H2O served as negative controls. B: Representative QPCR analysis of Anxa2r
in prostate cancer cell lines. Data are presented as the mean standard error
from three independent PCR reactions. C: Representative elements of a tissue
microarray in PCa stained with anti-Anxa2r antibody. C-1: Gleason grading 0.
C-2: Gleason grading 6. C-3: Gleason grading 7. C-4: Gleason grading 8.
C-5: Gleason grading 9. C-6: Gleason grading 10. Original magnification 20.
Scale bars¼ 100 mm.cells transfected with a scrambled siRNA (Fig. 5B). Similar results
were seen using the C4-2B and LNCaP cell lines (not presented).
Next, to explore the in vivo role of Anxa2r in PCa metastases,
PC-3siAnxa2r or PC-3siControl cells were injected i.c. into SCID mice.
At 1 month, significantly fewer lesions were identified in the
PC-3siAnxa2r cells injected group compared to those animals that
received the cells expressing the scrambled controls (Fig. 5C). These
data support the hypothesis that Anxa2r plays a critical role in PCa
metastasis.
Anxa2 REGULATES PCa PROLIFERATION AND SURVIVAL VIA
MAPK SIGNALING PATHWAY
To determine whether Anxa2 supports PCa survival or proliferation,
we examined the viability of PC-3Luc cells that were plated on
osteoblasts derived from Anxa2þ/þ or Anxa2/ mice. Significantly
more PC-3Luc cells grew on the Anxa2þ/þ osteoblasts than on the
Anxa2/ osteoblasts (Fig. 6A-1,2). To further explore whether
Anxa2 supports PCa growth in vivo, PC-3Luc cells were injected
directly into vertebral bodies (vossicles) derived from Anxa2þ/þ or
Anxa2/ animals, and transplanted into immunodeficient hosts.
Bioluminescent imaging was performed at one month to evaluate
luciferase activity in the implanted vossicles. The data demonstrated
that the growth of the PCa was greater in the vossicles derived from
Anxa2þ/þ animals (Fig. 6B-1,2). To explore how Anxa2 regulates
survival/growth, we next examined the effects of Anxa2 on Erk1/2
or Akt activation in PCa cells. PCa cells were treated with Anxa2,
and Akt and Erk1/2 phosphorylation were evaluated by western
blotting. The data demonstrated that Anxa2 rapidly induces Erk1/2
phosphorylation in PC-3 cells within 5 min, whereas Anxa2 did not376 ANNEXIN II REGULATES METASTASISactivate the Akt pathway (Fig. 6C). These data suggested that once
PCa has metastasized to the bone, Anxa2 then facilitates the PCa
growth via the MAPK pathway.
DISCUSSION
In this paper, we demonstrate that the Anxa2/Anxa2r axis plays a
crucial role in establishing metastasis of PCa by regulating the
adhesion and migration of PCa to osteobalsts and endothelial cells.
PCa cells migrate toward Anxa2 and the adhesion of PCa to
osteoblasts and endothelial cells was inhibited by an Anxa2 peptide,
and an anti-Anxa2 antibody and by siRNA knockdown of Anxa2r.
In in vivo studies, the short-term localization of PCa cells to a
number of tissues was substantially inhibited by Anxa2 peptides or
anti-Anxa2 antibodies. The long-term localization of PCa cells to a
number of tissues was also inhibited by siRNA knockdown of
Anxa2r. Moreover, Anxa2 is involved in the regulation of PCa
growth in vitro and in vivo by activating the MAPK signaling
pathway. Together, these data strongly suggested that Anxa2/
Anxa2r axis plays an important role in regulating the metastasis of
PCa to the marrow.JOURNAL OF CELLULAR BIOCHEMISTRY
Fig. 5. Anxa2r-targeting siRNAs specifically inhibit adhesion of prostate
cancer to endothelial cells in vitro, and tumor growth in vivo. PC-3Luc cells
were transfected with Anxa2r-targeting siRNAs (PC-3siAnxa2r cells) or scramble
control vector (PC-3siControl cells). A: The expression of Anxa2r was evaluated by
QPCR at 48 h after transfection. b-actin was included as a loading control. B:
Attachment of fluorescently labeled PC-3siAnxa2r or PC-3siControl cells to human
bone marrow endothelial cells (HBMECs) at 48C for 15 min. C: PC-3siAnxa2r or
PC-3siControl cells were injected systemically by intracardiac injection into SCID
mice. After a month, tumor growth was measured by a bioluminescent imaging.
Bioluminescence images are presented as the relative photon counts of each
individual (n¼ 10). Data are presented as the mean standard error. 	P< 0.05
and #P< 0.01 versus control.It is well known that HSCs localize to bone during fetal life and
during marrow transplantation. In the bone marrow, HSCs are
known to associate with at least 2 separate niches, the endosteal
niche (osteoblasts) and the vascular niche (endothelial cells). We
have recently demonstrated that osteoblasts and marrow endothelial
cells express Anxa2 which functions as a molecule that regulates
hematopoietic stem engraftment [Jung et al., 2007]. We have
hypothesized based upon the hematopoietic model that metastaticJOURNAL OF CELLULAR BIOCHEMISTRYPCa use a similar pathway to localize to the bone marrow [Taichman
et al., 2002]. Although both hematopoietic cells and PCa cells home
to the bone marrow, we are not aware of any investigation that
addresses whether Anxa2 operates in the pathogenesis of PCa
metastasis as an adhesion ligand. Our functional studies demon-
strate that Anxa2 alters the adherence, migration, and invasion of
human PCa cell lines. For example, it was observed that PCa cells
adhere to Anxa2 and that the N-terminal Anxa2 peptide
dramatically inhibited PCa binding to bone marrow-derived
endothelial cells. Moreover, it was demonstrated that Anxa2
supported the invasion of PCa cell lines into reconstituted
extracellular matrices, and that invasion stimulated by CXCL12
could be blocked by with Anxa2 itself or the N-terminal Anxa2
peptide. In fact, recently we observed that CXCL12 binds to Anxa2,
which could account for the loss of growth of PCa in Anxa2/
vossicles and why the addition of Anxa2 to the migration chambers
prevented chemotaxis to CXCL12 (Russell S. Taichman, unpublished
work). While specific transendothelial migration assays were not
performed, the initial binding of PCa cells to the endothelium is a
necessary prerequesite for egress of tumors out of the vascular
system. It was also demonstrated Anxa2 plays an important role in
regulating the binding between PCa and osteoblasts. To further
confirm the involvement of Anxa2 in the PCa metastasis, it was
found that blocking Anxa2 with a monoclonal antibody or N-
terminal peptide prevented PCa homing to the marrow and other
sites of PCa metastasis. Collectively, our results suggest that PCa
cells use Anxa2 as they spread to bone and other tissues.
Our data also suggest that Anxa2 may also regulate the
proliferation of PCa cells at metastatic sites. Moreover, ligand
binding of PCa cells to Anxa2 resulted in activation of Erk1/2
signaling. In bone, Anxa2 has been demonstrated to play a role in
osteoclastic activation and osteoblast mineralization, although the
mechanism for these actions remains unclear [Takahashi et al.,
1994; Wang and Kirsch, 2002]. One scenario is that extracellular
Anxa2 levels are regulated by 1,25-dihydroxyvitamin D3 that
stimulates the proliferation of osteoclastic precursors possibly
through T-cell intermediaries through the secretion of GM-CSF
[Menaa et al., 1999]. Osteoclastic activity is critical for PCa growth in
bone [Zhang et al., 2001]. Alternatively, Anxa2 may regulate
vascular in growth that is critical for tumor proliferation. Although
the detailed mechanisms for this remain unclear, Anxa2 may be
involved in the survival or growth of PCa either in a direct or
indirect way.
Work by our group and others have defined the role that CXCL12
and its receptors (CXCR4 and RDC1/CXCR7) play in the metastatic
process of PCa [Taichman et al., 2002; Sun et al., 2003, 2005, 2007;
Cooper et al., 2004; Wang et al., 2005, 2008; Havens et al., 2006]. In
PCa, we observed that CXCR4 expression relates to increasing tumor
grade [Sun et al., 2003] and that CXCL12 signaling through CXCR4
triggers the adhesion of PCa to bone marrow endothelial cells, by
activating CD164 [Havens et al., 2006] and avb3integrins [Sun et al.,
2007]. Moreover, a positive correlation exists between tissue levels
of CXCL12 and sites where metastatic PCa lesions are observed
suggesting a selective effect (pelvis, tibia, femur, liver, and adrenals)
[Sun et al., 2005]. Interestingly we found a significant number of
PCa cells in the prostate 24 h after i.c. injection. Previously we notedANNEXIN I I REGULATES METASTASIS 377
Fig. 6. Anxa2 facilitates the growth of prostate cancer in vitro and in vivo. A-1: The wild-type (Anxa2þ/þ OBs) or Anxa2/ mouse osteoblasts (Anxa2/ OBs) (10,000 cells/
well) were plated onto 96-well plates with 0.1% FBS. The next day, PC-3Luc cells (5,000 cells/well) were added on monolayers. At 72 h incubation at 378C, luciferase activity was
measured by a bioleuminescent imaging. A-2: The graph shows the percent change of luciferase activity shown in (A-1) (n¼ 6). Data are presented as the mean standard error.
#P< 0.01 versus control. B-1: Growth of PC3 cells in an Anxa2 deficient osseous environment. PC-3Luc cells were injected into Anxa2þ/þ and Anxa2/ mice vossicles and
transplanted into SCID mice (n¼ 12). At a month, the animals were imaged by a bioluminescent imaging. Data are presented as the relative photon counts of each individual.
	P< 0.05 versus control. B-2: Representative mice shown in (B-1). Individual animals were implanted with vossicles derived from either wild-type (Anxa2þ/þ) or Anxa2 deficient
animals. In some cases, these were seeded with PC3luc cells as shown in animal map. C: PC-3 cells were cultured in medium without FBS for 5 h. After serum starvation, the cells
were treated with 1,000 ng/ml Anxa2 peptide for 5, 15, 30, 45, and 60 min. Total protein was extracted and analyzed by Western blot for phosphorylated-Erk1/2 and Akt. Total
Erk1/2 and Akt were used as an internal control for loading.that PCa cells do disseminate back to the prostate from a s.c. tumor
[Havens et al., 2008]. The basis for these observations however
remains unclear. One of the mechanisms for this could be that
prostate tissue expresses CXCL12 [Berquin et al., 2005]. Another
could be that PCa cells are attracted to the primary site possibly due
to other homing mechanisms or because of its ‘‘fertile soil.’’ Further
studies will be needed to sort out these possibilities.
While CXCL12 and its receptors participate in the homing of PCa
to the niche, the events activated by PCa to co-opt the niche remain
unclear. It is tantalizing to hypothesize that one of the potential
reasons why metastatic PCa induce the expression of an osteoblastic
phenotype is to establish a paracrine loop to further support their
expansion/growth through enhanced production of CXCL12 and
Anxa2. For example, Anxa2 itself is associated with proliferating
and invasive cancers, possibly as a marker of malignancy [Reeves
et al., 1992] including lung, pancreatic, brain, colon, and gastric
carcinomas, and is correlated with poor prognosis [Cole et al., 1992;378 ANNEXIN II REGULATES METASTASISVishwanatha et al., 1993; Roseman et al., 1994; Emoto et al., 2001;
Diaz et al., 2004]. Yet, the loss of Anxa2 expression appears to be
specific for PCa disease [Chetcuti et al., 2001; Banerjee et al., 2003;
Kirshner et al., 2003; Liu et al., 2003; Smitherman et al., 2004;
Semov et al., 2005]. Therefore, it is possible that the absence of
Anxa2 places selective pressures on PCa tumors to metastasize to
bone, a rich source of Anxa2.
It is also possible that Anxa2 serves as an adhesion molecule for
PCa such that blocking Anxa2 or its receptor limits metastasis and
subsequent tumor growth. Part of the mechanism may be that
engagement of Anxa2 receptors on PCa stimulates the expression of
a number of other receptors on PCa, many of which may be activated
by proliferative signals including CXCR4. Thus, a ‘‘vicious cycle’’
would be established by PCa in which increases in osteoblast
numbers expand niche size by increasing the availability of Anxa2
and CXCL12. As a result, tumor expansion in the marrow may result
by providing a docking signal that is normally absent (i.e., Anxa2)JOURNAL OF CELLULAR BIOCHEMISTRY
and promotion of proliferation (i.e., CXCL12), which may explain
why bone metastases are so difficult to treat clinically. While further
studies are clearly needed, these data suggest that Anxa2/Anxa2r
plays a significant role in the metastatic cascades of PCa and thereby
suggest novel targets for therapeutic intervention to prevent PCa
metastasis.
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